> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Sanofi Aventis NDAs for Diabetes
- URL: https://www.fdaweb.com/panel-to-discuss-sanofi-aventis-ndas-for-diabetes/
- Published: 2016-03-16T12:00:00.000Z
- Updated: 2026-09-15T02:44:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135104

*Federal Register* Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 5/24, from 8 a.m. to 5 p.m. at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss the safety and efficacy of Sanofi Aventis NDAs for insulin glargine and lixisenatide injection, a fixed ratio drug product consisting of insulin and a GLP-1 receptor agonist, and for lixisenatide injection, a GLP-1 receptor agonist, submitted proposed for treating adults with Type 2 diabetes mellitus. Contact **LaToya Bonner**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-16/pdf/2016-05931.pdf?ref=fdaweb.com)